<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042871</url>
  </required_header>
  <id_info>
    <org_study_id>2015002</org_study_id>
    <nct_id>NCT03042871</nct_id>
  </id_info>
  <brief_title>Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization</brief_title>
  <acronym>SMILE</acronym>
  <official_title>Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy (times of injection, change of visual
      acuity and Cva/ I) and safety (macular visual function and choroidal thickness) of different
      dosing of ranibizumab intravitreal injection (1+PRN vs. 3+PRN) in treating with pathological
      myopia choroidal neovascularization (PM-CNV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PM is a common disease in east asia, while PM-CNV affect 5%-10% PM patients.PM-CNV has
      specific characteristics, including small dimensions and limited exudative manifestations
      comparing with age-related macular degeneration. However, treatment regimen and re-treatment
      criteria follow the PrONTO protocol. The question of the optimal dose and treatment regimen
      in myopic CNV management is still unresolved. There is no unequivocal evidence suggesting hat
      PRN treatment is more effective than a loading phase followed by an as-needed variable dosage
      regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>Baseline and monthly after enrollment from baseline up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal sensitivities on microperimetry</measure>
    <time_frame>Baseline and monthly after enrollment from baseline up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical response densities in the foveal on multifocal electroretinogram</measure>
    <time_frame>Baseline, 3 months, 6 months and 12 months after enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations of optic coherence tomography angiography</measure>
    <time_frame>Baseline, 3 months, 6 months and 12 months after enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness on optic coherence tomography</measure>
    <time_frame>Baseline and monthly after enrollment up to 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leakage in lesion on fluorescein fundus angiography</measure>
    <time_frame>Baseline, 3 months, 6 months and 12 months after enrollment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fixation stability on microperimetry</measure>
    <time_frame>Baseline and monthly after enrollment from baseline up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5mg intravitreal ranibizumab</intervention_name>
    <description>Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>IVR 0.5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older then 18 years old

          -  refractive error ≥ -6.0 diopters or axial length ≥ 26.0mm

          -  active CNV due to high myopic which is the only reason cause visual loss confirmed by
             fluorescein fundus angiography

          -  BCVA ≥ 24.0 and ≤73 letters at a starting distance of 4 meters using Early Treatment
             Diabetic Retinopathy Study visual acuity chart.

        Exclusion Criteria:

          -  history of (a) stroke,(b) laser photocoagulation involved macular area in study eye,
             (c) intraocular treatment with corticosteroids or intraocular surgery or anti vascular
             endothelial growth factor or verteporfin photodynamic therapy within 6 months in study
             eye, or (d) hypersensitivity to ranibizumab or fluorescein

          -  presence of active infectious disease or confirmed intraocular pressure ≥ 21.0 mmHg

          -  pregnant or nursing women

          -  uncontrolled high blood pressure ≥ 150/90 mmHg or uncontrolled fasting blood glucose ≥
             7 mmol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoyan Ding, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ZZhongShan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoyan Ding, PhD</last_name>
    <phone>+861353502222</phone>
    <email>dingxy75@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZhongShan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Ding, phD</last_name>
      <phone>+8613535022222</phone>
      <email>dingxy75@gamil.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.gzzoc.com/ykyj/zdsys/</url>
    <description>Website of Ophthalmic Research Institute/Laboratory, ZhongShan Ophthalmic Center, Sun Yat-sen University</description>
  </link>
  <reference>
    <citation>Van Newkirk MR. The Hong Kong vision study: a pilot assessment of visual impairment in adults. Trans Am Ophthalmol Soc. 1997;95:715-49.</citation>
    <PMID>9440191</PMID>
  </reference>
  <reference>
    <citation>Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003 Jul;110(7):1297-305.</citation>
    <PMID>12867382</PMID>
  </reference>
  <reference>
    <citation>Wong TY, Foster PJ, Hee J, Ng TP, Tielsch JM, Chew SJ, Johnson GJ, Seah SK. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2486-94.</citation>
    <PMID>10937558</PMID>
  </reference>
  <reference>
    <citation>Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005 Nov;89(11):1522-8. Review.</citation>
    <PMID>16234465</PMID>
  </reference>
  <reference>
    <citation>Jones D, Luensmann D. The prevalence and impact of high myopia. Eye Contact Lens. 2012 May;38(3):188-96. doi: 10.1097/ICL.0b013e31824ccbc3. Review.</citation>
    <PMID>22495679</PMID>
  </reference>
  <reference>
    <citation>Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci. 2006 May;83(5):316-25. Review.</citation>
    <PMID>16699445</PMID>
  </reference>
  <reference>
    <citation>Sun J, Zhou J, Zhao P, Lian J, Zhu H, Zhou Y, Sun Y, Wang Y, Zhao L, Wei Y, Wang L, Cun B, Ge S, Fan X. High prevalence of myopia and high myopia in 5060 Chinese university students in Shanghai. Invest Ophthalmol Vis Sci. 2012 Nov 1;53(12):7504-9. doi: 10.1167/iovs.11-8343.</citation>
    <PMID>23060137</PMID>
  </reference>
  <reference>
    <citation>Nagaoka N, Shimada N, Hayashi W, Hayashi K, Moriyama M, Yoshida T, Tokoro T, Ohno-Matsui K. Characteristics of periconus choroidal neovascularization in pathologic myopia. Am J Ophthalmol. 2011 Sep;152(3):420-427.e1. doi: 10.1016/j.ajo.2011.03.002. Epub 2011 Jun 22.</citation>
    <PMID>21696698</PMID>
  </reference>
  <reference>
    <citation>Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001 May;108(5):841-52.</citation>
    <PMID>11320011</PMID>
  </reference>
  <reference>
    <citation>Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003 Apr;110(4):667-73.</citation>
    <PMID>12689884</PMID>
  </reference>
  <reference>
    <citation>Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol. 2005 Oct;89(10):1368-70. Erratum in: Br J Ophthalmol. 2006 Jan;90(1):125.</citation>
    <PMID>16170134</PMID>
  </reference>
  <reference>
    <citation>Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M; RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014 Mar;121(3):682-92.e2. doi: 10.1016/j.ophtha.2013.10.023. Epub 2013 Dec 8.</citation>
    <PMID>24326106</PMID>
  </reference>
  <reference>
    <citation>Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014 Jan;121(1):150-61. doi: 10.1016/j.ophtha.2013.08.015. Epub 2013 Sep 29.</citation>
    <PMID>24084496</PMID>
  </reference>
  <reference>
    <citation>Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol. 2014 Dec;92(8):e615-20. doi: 10.1111/aos.12457. Epub 2014 Jun 12.</citation>
    <PMID>24924911</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiaoyan Ding</investigator_full_name>
    <investigator_title>Professor,PhD,MD</investigator_title>
  </responsible_party>
  <keyword>PM-CNV ,Ranibizumab, Dosing Strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

